WO2001016163A3 - Peptide mixture and vaccine against a chronic viral infection - Google Patents

Peptide mixture and vaccine against a chronic viral infection Download PDF

Info

Publication number
WO2001016163A3
WO2001016163A3 PCT/EP2000/008124 EP0008124W WO0116163A3 WO 2001016163 A3 WO2001016163 A3 WO 2001016163A3 EP 0008124 W EP0008124 W EP 0008124W WO 0116163 A3 WO0116163 A3 WO 0116163A3
Authority
WO
WIPO (PCT)
Prior art keywords
hepatitis
peptide mixture
viral infection
vaccine against
mixture
Prior art date
Application number
PCT/EP2000/008124
Other languages
French (fr)
Other versions
WO2001016163A2 (en
Inventor
Catharina Hultgren
Matti Saellberg
Original Assignee
Eurodiagnostica Ab
Catharina Hultgren
Matti Saellberg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eurodiagnostica Ab, Catharina Hultgren, Matti Saellberg filed Critical Eurodiagnostica Ab
Priority to JP2001519724A priority Critical patent/JP2003508409A/en
Priority to AU79031/00A priority patent/AU7903100A/en
Priority to EP00969241A priority patent/EP1206278A2/en
Publication of WO2001016163A2 publication Critical patent/WO2001016163A2/en
Publication of WO2001016163A3 publication Critical patent/WO2001016163A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Disclosed is a peptide mixture, a pharmaceutical composition and a vaccine against a chronic infection caused by a virus comprising a mixture of 10 to 30 amino acids (aa) long peptides each with a 5 to 25 aa overlap of the adjacent overlapping peptide spanning the amino acid sequence of a viral protein of said virus, e.g. Hepatitis B, Hepatitis C, GBvirus-C, HIV and Herpes viruses. Hepatitis B has been used as an example and it is demonstrated that a peptide mixture composed of seventeen 20 to 23 aa long peptides spanning the amino acids 1 to 183 of the hepatitis B core antigen (HBcAg) could activate specific T cells regardless of the host MHC/HLA genotype that recognize the native protein processed by professional antigen presenting cells (APCs). Further, a method is described for the treatment of a viral infection, particularly a non-resolving chronic viral infection, making use of the novel peptide mixture immunogen.
PCT/EP2000/008124 1999-08-27 2000-08-21 Peptide mixture and vaccine against a chronic viral infection WO2001016163A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2001519724A JP2003508409A (en) 1999-08-27 2000-08-21 Peptide mixtures and vaccines against chronic viral infections
AU79031/00A AU7903100A (en) 1999-08-27 2000-08-21 Peptide mixture and vaccine against a chronic viral infection
EP00969241A EP1206278A2 (en) 1999-08-27 2000-08-21 Peptide mixture and vaccine against a chronic viral infection

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9903031-4 1999-08-27
SE9903031A SE9903031D0 (en) 1999-08-27 1999-08-27 Peptide mixture and vaccine against a chronic viral infection

Publications (2)

Publication Number Publication Date
WO2001016163A2 WO2001016163A2 (en) 2001-03-08
WO2001016163A3 true WO2001016163A3 (en) 2001-09-07

Family

ID=20416772

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2000/008124 WO2001016163A2 (en) 1999-08-27 2000-08-21 Peptide mixture and vaccine against a chronic viral infection

Country Status (5)

Country Link
EP (1) EP1206278A2 (en)
JP (1) JP2003508409A (en)
AU (1) AU7903100A (en)
SE (1) SE9903031D0 (en)
WO (1) WO2001016163A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9416416B2 (en) 2007-10-01 2016-08-16 Longhorn Vaccines And Diagnostics, Llc Biological specimen collection/transport compositions and methods
US9481912B2 (en) 2006-09-12 2016-11-01 Longhorn Vaccines And Diagnostics, Llc Compositions and methods for detecting and identifying nucleic acid sequences in biological samples

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2824326B1 (en) * 2001-05-04 2004-03-19 Commissariat Energie Atomique MIXTURE OF PEPTIDES FROM PAPILLOMAVIRUS E6 AND / OR E7 PROTEINS AND THEIR APPLICATIONS
US7351413B2 (en) 2002-02-21 2008-04-01 Lorantis, Limited Stabilized HBc chimer particles as immunogens for chronic hepatitis
CA2528727A1 (en) * 2003-06-10 2004-12-16 The University Of Melbourne Immunomodulating compositions, uses therefor and processes for their production
GB0608368D0 (en) * 2006-04-28 2006-06-07 Isis Innovation Process for making Oligopeptides
BRPI0713978A2 (en) * 2006-06-28 2012-11-27 Statens Seruminstitut expansion of t-cell repertoire to include subdominant epitopes by vaccination with leber antigen such as protein fragments or peptide cocktails
US8097419B2 (en) 2006-09-12 2012-01-17 Longhorn Vaccines & Diagnostics Llc Compositions and method for rapid, real-time detection of influenza A virus (H1N1) swine 2009
US11041215B2 (en) 2007-08-24 2021-06-22 Longhorn Vaccines And Diagnostics, Llc PCR ready compositions and methods for detecting and identifying nucleic acid sequences
US10004799B2 (en) 2007-08-27 2018-06-26 Longhorn Vaccines And Diagnostics, Llc Composite antigenic sequences and vaccines
CA2697373C (en) 2007-08-27 2019-05-21 Longhorn Vaccines & Diagnostics, Llc Immunogenic compositions and methods
EP2106803A1 (en) 2008-04-04 2009-10-07 Fondazione Centro San Raffaele del Monte Tabor Method to design and uses of overlapping peptides for monitoring T-cell responses in HIV patients
CN102060929A (en) * 2010-06-07 2011-05-18 夏书奇 T-cell immune balance peptide
JP6758185B2 (en) * 2013-12-13 2020-09-23 ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ Multiepitope TARP peptide vaccine and its use
JP2022535458A (en) * 2019-06-07 2022-08-08 オレゴン ヘルス アンド サイエンス ユニバーシティ Hepatitis B virus-specific T-cell responses

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993014206A2 (en) * 1992-01-20 1993-07-22 Connaught Laboratories Limited Synthetic peptides for a rubella vaccine
WO1993018054A2 (en) * 1992-03-06 1993-09-16 N.V. Innogenetics S.A. Process for the determination of peptides corresponding to immunologically important epitopes and their use in a process for determination of antibodies or biotinylated peptides corresponding to immunologically important epitopes, a process for preparing them and compositions containing them
WO1996022067A2 (en) * 1994-12-27 1996-07-25 United Biomedical, Inc. Peptide ratchet libraries for ctl-inducing vaccines and therapeutics

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993014206A2 (en) * 1992-01-20 1993-07-22 Connaught Laboratories Limited Synthetic peptides for a rubella vaccine
WO1993018054A2 (en) * 1992-03-06 1993-09-16 N.V. Innogenetics S.A. Process for the determination of peptides corresponding to immunologically important epitopes and their use in a process for determination of antibodies or biotinylated peptides corresponding to immunologically important epitopes, a process for preparing them and compositions containing them
WO1996022067A2 (en) * 1994-12-27 1996-07-25 United Biomedical, Inc. Peptide ratchet libraries for ctl-inducing vaccines and therapeutics

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BRUNA-ROMERO O ET AL: "Induction of Cytotoxic T-Cell Response Against Hepatitis C Virus Structural Antigens Using a Defective Recombinant Adenovirus", HEPATOLOGY, vol. 25, no. 2, 1997, pages 470 - 477, XP002901538 *
TSAI S L ET AL: "Characterization of T Cell Clones Specific to a Determinant of Hepatitus B Virus Core and e Antigens in Chronic Type B Hepatitus : Implication for a T Cell Mechanism of HBV Immunopathogenesis", J BIOMED SCI, vol. 1, 1994, pages 105 - 118, XP002901537 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9481912B2 (en) 2006-09-12 2016-11-01 Longhorn Vaccines And Diagnostics, Llc Compositions and methods for detecting and identifying nucleic acid sequences in biological samples
US9416416B2 (en) 2007-10-01 2016-08-16 Longhorn Vaccines And Diagnostics, Llc Biological specimen collection/transport compositions and methods

Also Published As

Publication number Publication date
EP1206278A2 (en) 2002-05-22
AU7903100A (en) 2001-03-26
JP2003508409A (en) 2003-03-04
SE9903031D0 (en) 1999-08-27
WO2001016163A2 (en) 2001-03-08

Similar Documents

Publication Publication Date Title
WO2001016163A3 (en) Peptide mixture and vaccine against a chronic viral infection
Wiktor et al. Antigenic properties of rabies virus components
US7709003B2 (en) Method of producing an HIV-1 immune response
AU2774389A (en) Recombinant vaccinia virus mva
CA2660355A1 (en) Polynucleotide vaccine formulation against pathologies of the horse
DK0596979T3 (en) Plant virus recombinant nucleic acids
NO167359C (en) PROCEDURE FOR THE PREPARATION OF A VACCINE AGAINST INFECTION OF HEPATITIS B VIRUS.
DE68928130D1 (en) Synthetic peptides derived from HIV-GP120-env protein and their application
ES2075440T3 (en) VACCINE AGAINST HEPATITIS B.
WO2004004761A3 (en) Adjuvant viral particle
RU2319505C2 (en) Purified coat proteins of hepatitis c virus for diagnostic and therapeutic application
WO2002074920A3 (en) A replication-defective alphavirus vaccine linking antigen with an immunogenicity-potentiating polypeptide and a method of delivery the same
IE870507L (en) Bovine virus diarrhea and hog cholera vaccines
EP0327180A3 (en) Vaccine containing polypeptides derived from the envelope gene of human immunodeficiency virus type 1
EP1878797A3 (en) Antigenic peptides for grouping hepatitis c virus, kit comprising the same and methods for its grouping using the same
KR950005326A (en) Recombinant Adenovirus Vaccine
US4946676A (en) Vaccine comprising an immunogenic protein and, as an adjuvant, a substantially non-immunogenic, sequentially homologous peptide
RU2313363C2 (en) Hepatitis virus c envelope purified protein for diagnostic and therapeutic application
WO2007127290A3 (en) Method for producing viral vaccine and therapeutic peptide antigens
WO2001055330A3 (en) Recombinant rhabdoviruses as live-viral vaccines for immunodeficiency viruses
GB9925966D0 (en) Threapeutic vaccines against variable viruses and other targets
AU6839598A (en) Antigenic structural peptide, antigenic and immunogenic compounds and uses for detecting, preventing and treating an hcv infection
WO2002089728A3 (en) Recombinant rhabdoviruses as live-viral vaccines
AU2004200155C1 (en) HIV peptides, antigens, vaccine compositions, immunoassay kit and a method of detecting antibodies induced by HIV
Ivanoff et al. Human immunodeficiency virus antigen.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2000969241

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000969241

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10069109

Country of ref document: US

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2000969241

Country of ref document: EP